Improving Life Quality in Older Frail Patients with Blood Cancers Using Geriatric Assessment and Treatment A Randomized Controlled Study

What this Trial Is About

Researchers are evaluating the effect of adding comprehensive geriatric assessment CGA and related treatment to the usual care in older, frail patients with blood cancers. This randomized controlled trial aims to compare the quality of life and functional status between patients receiving CGA integrated with their cancer treatment and those receiving the standard hematological care. The study targets patients aged 70 years or older with various hematologic malignancies who are frail and undergoing systemic cancer treatment. Participants will be randomly assigned to either receive the intervention, which involves a detailed CGA performed by a geriatric specialists team including assessment of comorbidities, medications, symptoms, physical function, and living conditions, with relevant follow-up treatments or to a control group receiving standard hematological evaluation and care. The CGA is done before or shortly after starting cancer treatment and does not delay necessary therapy. Cancer treatment itself follows standard guidelines and is not altered by study participation. During the 52-week study period, participants will undergo physical tests such as the 30-second chair stand test and handgrip strength assessments at baseline, 12, and 26 weeks. Researchers will collect data on treatment toxicity, adherence to the cancer treatment plan, medication use, hospitalizations, and survival outcomes. Quality of life questionnaires will also be completed. The primary outcome is the elderly functional index measured at 12 and 26 weeks. Monitoring includes ongoing review of medical records and follow-up visits to assess health and treatment effects.

Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment